Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

LGX818

HY-15605

(Encorafenib; LGX 818; LGX-818)

LGX818

LGX818 Chemical Structure

LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $428 In-stock
1 mg $105 In-stock
5 mg $360 In-stock
10 mg $550 In-stock
50 mg Get quote
100 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €419 In-stock
1 mg €103 In-stock
5 mg €353 In-stock
10 mg €539 In-stock
50 mg Get quote
100 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: LGX818
Cat. No.: HY-15605

LGX818 Data Sheet

  • View current batch:

    Purity: 99.76%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of LGX818

LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.
IC50 value: 0.3 nM (BRaf V600E biochemical); 2 nM (A375 cell proliferation) [1]
Target: mutated BRaf V600E
LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis, is in phase III clinical trials, and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans. More information can be found in Patent WO2011025927A1

 

Chemical Information

M.Wt 540.01 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C22H27ClFN7O4S
CAS No 1269440-17-6
Solvent & Solubility

in DMSO > 10 mM

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.8518 mL 9.2591 mL 18.5182 mL
5 mM 0.3704 mL 1.8518 mL 3.7036 mL
10 mM 0.1852 mL 0.9259 mL 1.8518 mL

References on LGX818

Inhibitor Kit

Related Raf Products

  • AZ 628

    AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.

  • B-Raf IN 1

    B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor with IC50 of 24 nM; equipotent against c-Raf (IC50= 25 nM).

  • B-Raf inhibitor

    A B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

  • BRAF inhibitor

    BRAF inhibitor is a potent BRAF inhibitor.

  • GDC-0879

    GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well; no inhibition known to other protein kinases.

  • GW 5074

    GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

  • HG6-64-1

    HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.

  • L-779450

    L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38(alpha), GSK3(beta) and Lck respectively.

  • LY3009120

    LY3009120 is a small molecule that has been shown in vitro to be a pan-RAF inhibitor of all isoforms, blocking proliferation in both BRAF and RAS mutant cells.

  • MLN 2480

    MLN 2480(BIIB-024) is an oral, selective pan-Raf kinase inhibitor in chinical trials.

MORE